Literature DB >> 11281555

Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation.

A Berson1, D Fau, R Fornacciari, P Degove-Goddard, A Sutton, V Descatoire, D Haouzi, P Lettéron, A Moreau, G Feldmann, D Pessayre.   

Abstract

BACKGROUND/AIMS: Although sublingual buprenorphine is safely used as a substitution drug in heroin addicts, large overdoses or intravenous misuse may cause hepatitis. Buprenorphine is N-dealkylated to norbuprenorphine by CYP3A.
METHODS: We investigated the mitochondrial effects and metabolic activation of buprenorphine in isolated rat liver mitochondria and microsomes, and its toxicity in isolated rat hepatocytes and treated mice.
RESULTS: Whereas norbuprenorphine had few mitochondrial effects, buprenorphine (25-200 microM) concentrated in mitochondria, collapsed the membrane potential, inhibited beta-oxidation, and both uncoupled and inhibited respiration in rat liver mitochondria. Both buprenorphine and norbuprenorphine (200 microM) underwent CYP3A-mediated covalent binding to rat liver microsomal proteins and both caused moderate glutathione depletion and increased cell calcium in isolated rat hepatocytes, but only buprenorphine also depleted cell adenosine triphosphate (ATP) and caused necrotic cell death. Four hours after buprenorphine administration to mice (100 nmol/g body weight), hepatic glutathione was unchanged, while ATP was decreased and serum transaminase increased. This transaminase increase was attenuated by a CYP3A inducer and aggravated by a CYP3A inhibitor.
CONCLUSIONS: Both buprenorphine and norbuprenorphine undergo metabolic activation, but only buprenorphine impairs mitochondrial respiration and ATP formation. The hepatotoxicity of high concentrations or doses of buprenorphine is mainly related to its mitochondrial effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11281555     DOI: 10.1016/s0168-8278(00)00050-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

1.  Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.

Authors:  Jeanette M Tetrault; Janet P Tate; E Jennifer Edelman; Adam J Gordon; Vincent Lo Re; Joseph K Lim; David Rimland; Joseph Goulet; Stephen Crystal; Julie R Gaither; Cynthia L Gibert; Maria C Rodriguez-Barradas; Lynn E Fiellin; Kendall Bryant; Amy C Justice; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2016-06-06

Review 2.  Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.

Authors:  Andrew H Talal; Charles S Venuto; Islam Younis
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

3.  The Influence of Liver Resection on Intrahepatic Tumor Growth.

Authors:  Hannes H Brandt; Valérie Nißler; Roland S Croner
Journal:  J Vis Exp       Date:  2016-04-09       Impact factor: 1.355

Review 4.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

5.  Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.

Authors:  David A Fiellin; Linda Weiss; Michael Botsko; James E Egan; Frederick L Altice; Lauri B Bazerman; Amina Chaudhry; Chinazo O Cunningham; Marc N Gourevitch; Paula J Lum; Lynn E Sullivan; Richard S Schottenfeld; Patrick G O'Connor
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

6.  Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058.

Authors:  Gregory M Lucas; Geetha Beauchamp; Apinun Aramrattana; Yiming Shao; Wei Liu; Liping Fu; J Brooks Jackson; David D Celentano; Paul Richardson; David Metzger
Journal:  Int J Drug Policy       Date:  2011-08-17

7.  Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.

Authors:  Gregory M Lucas; Alicia Young; Deborah Donnell; Paul Richardson; Apinun Aramrattana; Yiming Shao; Yuhua Ruan; Wei Liu; Liping Fu; Jun Ma; David D Celentano; David Metzger; J Brooks Jackson; David Burns
Journal:  Drug Alcohol Depend       Date:  2014-06-19       Impact factor: 4.492

8.  Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial.

Authors:  Andrew J Saxon; Walter Ling; Maureen Hillhouse; Christie Thomas; Albert Hasson; Alfonso Ang; Geetha Doraimani; Gudaye Tasissa; Yuliya Lokhnygina; Jeff Leimberger; R Douglas Bruce; John McCarthy; Katharina Wiest; Paul McLaughlin; Richard Bilangi; Allan Cohen; George Woody; Petra Jacobs
Journal:  Drug Alcohol Depend       Date:  2012-08-22       Impact factor: 4.492

9.  Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication.

Authors:  Laura F McNicholas; Amber M Holbrook; Kevin E O'Grady; Hendrée E Jones; Mara G Coyle; Peter R Martin; Sarah H Heil; Susan M Stine; Karol Kaltenbach
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

Review 10.  Practical considerations for the clinical use of buprenorphine.

Authors:  Hendree E Jones
Journal:  Sci Pract Perspect       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.